TVGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 56.60%

Insider Buying (Last 12 Months): $2,460.00

Insider Selling (Last 12 Months): $2,194,094.50

Tevogen Bio Insider Trading History Chart

Tevogen Bio Share Price & Price History

^$1.13

▼ -0.035 (-3.02%)

As of 03/18/2025 11:04 AM ET

Days: 30 | 90 | 365

Tevogen Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2025	Neal Flomenberg	Insider	Sell	232,968	$1.09	$253,935.12	3,595,608
3/10/2025	Neal Flomenberg	Insider	Sell	70,384	$1.09	$76,718.56	3,898,828
3/6/2025	Neal Flomenberg	Insider	Sell	88,519	$1.10	$97,370.90	4,040,485
3/4/2025	Neal Flomenberg	Insider	Sell	14,639	$1.28	$18,737.92	4,239,663
10/17/2024	Neal Flomenberg	Insider	Sell	1,078,600	$1.62	$1,747,332.00	4,254,302
6/12/2024	Kirti Desai	CFO	Buy	3,000	$0.82	$2,460.00	9,699,186

SEC Filings (Institutional Ownership Changes) for Tevogen Bio (NASDAQ:TVGN)

Institutional Buying and Selling by Quarter

Tevogen Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2025	Northern Trust Corp	118,415	$0.12M	0.0%	+13.0%	0.068%
2/13/2025	XTX Topco Ltd	53,858	$55K	0.0%	N/A	0.031%
2/13/2025	Barclays PLC	45,600	$48K	0.0%	+39.2%	0.026%
2/12/2025	Geode Capital Management LLC	451,851	$0.47M	0.0%	+31.2%	0.258%
2/12/2025	JPMorgan Chase & Co.	39,207	$40K	0.0%	+74.2%	0.022%
1/24/2025	China Universal Asset Management Co. Ltd.	37,117	$38K	0.0%	N/A	0.021%
11/15/2024	Polar Asset Management Partners Inc.	1,577,387	$0.58M	0.0%	-20.6%	0.924%
11/15/2024	HGC Investment Management Inc.	223,077	$82K	0.0%	N/A	0.131%
5/9/2024	Portland Global Advisors LLC	5,782,209	$21.68M	3.0%	N/A	36.550%

Data available starting January 2016

See Full Table

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Today's Range

Now: $1.13

$1.12

$1.16

50 Day Range

MA: $1.36

$1.06

$1.68

52 Week Range

Now: $1.13

$0.26

$6.25

Volume

46,049 shs

Average Volume

5,067,945 shs

Market Capitalization

$196.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Tevogen Bio?: Tevogen Bio's top insider investors include:
Kirti Desai (CFO)
Neal Flomenberg (Insider)
Learn More about top insider investors at Tevogen Bio.
Who are the major institutional investors of Tevogen Bio?: Tevogen Bio's top institutional investors include:
Geode Capital Management LLC — 0.26%
Northern Trust Corp — 0.07%
XTX Topco Ltd — 0.03%
Barclays PLC — 0.03%
JPMorgan Chase & Co. — 0.02%
China Universal Asset Management Co. Ltd. — 0.02%
Learn More about top institutional investors of Tevogen Bio stock.
Which institutional investors are buying Tevogen Bio stock?: During the previous quarter, TVGN stock was acquired by institutional investors including:
Geode Capital Management LLC
XTX Topco Ltd
China Universal Asset Management Co. Ltd.
JPMorgan Chase & Co.
Northern Trust Corp
Barclays PLC